Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Regeneron Pharmaceuticals is conducting a Phase 2 clinical trial titled ‘A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC.’ The study aims to evaluate the safety and efficacy of combining fianlimab, cemiplimab, and chemotherapy compared to cemiplimab and chemotherapy alone in patients with non-small cell lung cancer (NSCLC) that can be surgically treated.
The trial tests the combination of drugs, including fianlimab, cemiplimab, and platinum-doublet chemotherapy, to determine if they work better together than cemiplimab and chemotherapy alone. The study also explores potential side effects, drug levels in the blood, and the body’s immune response to the drugs.
This interventional study is randomized and uses a parallel assignment model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose is treatment-focused.
The study began on July 16, 2024, with a primary completion date yet to be announced. The latest update was submitted on June 23, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The outcome of this study could significantly impact Regeneron’s stock performance and investor sentiment, especially if the combination therapy proves more effective. This could position Regeneron favorably against competitors in the oncology market.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.